NCT05375370Recruiting
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Monitoring Circulating Tumor DNA: a Prospective Cohort Study
Source: ClinicalTrials.gov · Last updated 6 Feb 2026
Brief summary (registry, in English)
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer. In order to meet this objective, this biomarker will be measured in your blood before and after surgery, at three and six months.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 10 May 2022
- Start date
- Aug 2022
- Primary completion date
- Feb 2029
- Lead sponsor
- University Hospital, Rouen
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT05375370
What you commit to
- Study type: Interventional
- Planned participants: 150
- From Aug 2022 to the primary completion date, Feb 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Contra-indication to surgery
Other illness
- Other active cancer or hematological malignancy
Other
- Patient not affiliated to the social security system
- Pregnant woman or parturient or breastfeeding
- Person under court protection, sub guardianship or curatorship
Who the study is looking for
- Age ≥ 18 years
- HCC diagnosed on consensus radiological criteria in cirrhotic patients (EASL-EORTC 2012): helical CT or MRI with triple arterial, portal and late acquisition. The diagnosis is based on the presence of hypervascularization at the early arterial time (wash-in) with wash-out (hypodensity or hypointensity compared to non-tumor liver parenchyma) at the portal phase or late phase compared to non-tumor parenchyma.
- HCC diagnosed histologically in the absence of a diagnosis on imaging (see IC n°2 above)
- Patient operated on for liver resection or radiofrequency destruction
- Treatment decision validated by the digestive oncology PCR
- Patient having read and understood the information letter and signed the non-opposition form
- Patient follow-up at the Charles Nicolle University Hospital in Rouen
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Rouen Coordinator of this site? Confirm its status | Rouen | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.